Study guide
23.1 Interim Visit Preparation and Consent Review
ACRP CCRA Certified Clinical Research Associate Study Guide 2026 Exam
Track your progress as you read
Finished sections get a check mark.
1 Chapter 1: Exam Format, Eligibility and Registration
1.1 Exam Format, Eligibility and Current References 1.2 Registration, Fees and Candidate Decisions
2 Chapter 2: CRA Responsibilities and Study Planning
2.1 The CRA Role, Data Integrity and Product Oversight 2.2 Official Blueprint and Study Strategy
3 Chapter 3: Protocols, Endpoints and Trial Design
3.1 Protocol Elements and Endpoint Hierarchy 3.2 Endpoint Interpretation and Eligibility Rationale 3.3 Eligibility Verification and Trial Designs
4 Chapter 4: Bias Control, Blinding and Product Information
4.1 Bias, Randomisation and Comparator Controls 4.2 Unblinding and Investigator Brochure Content 4.3 Reference Safety Information and IB Updates
5 Chapter 5: Estimands and Device Instructions
5.1 Estimands and Intercurrent Events 5.2 Device Instructions, Configuration and Training
6 Chapter 6: Ethical Foundations and Independent Oversight
6.1 Ethical Foundations and the 2024 Declaration of Helsinki 6.2 Vulnerability, Voluntariness and Compensation 6.3 IRB/IEC Composition and Independent Review
7 Chapter 7: Ethics Communication and Informed Consent
7.1 Ethics Reporting, Approval Status and Version Control 7.2 Informed Consent Information and Meaningful Choice 7.3 Consent Documentation, Special Circumstances and Updates
8 Chapter 8: Recruitment, Retention and Confidentiality
8.1 Ethical Eligibility, Recruitment and Retention 8.2 Privacy, Confidentiality and Appropriate Access
9 Chapter 9: Safety Definitions and Classification
9.1 Adverse Event Definitions and Actual Life-Threatening Risk 9.2 Seriousness, Severity and Medical Importance 9.3 Causality, Expectedness and Reference Safety Information
10 Chapter 10: Safety Detection, Reporting and Oversight
10.1 Detecting Events, AESIs and Collection Windows 10.2 Expedited Reporting and the Sponsor Awareness Clock 10.3 Immediate Site Reporting and Independent Safety Oversight
11 Chapter 11: Follow-Up, Adherence and Conflicts
11.1 Safety Communications, Reconciliation and Follow-Up 11.2 Adherence, Discontinuation and Participant Choice 11.3 Conflicts of Interest and Prorated Payments
12 Chapter 12: Development Stages and Product Management
12.1 Nonclinical Background and Human Pharmacology 12.2 Exploratory, Confirmatory and Therapeutic-Use Studies 12.3 Product Storage, Labelling and Excursion Response
13 Chapter 13: Accountability, Integrity and Regulatory Status
13.1 Product Accountability and Adherence Calculations 13.2 Potential Fraud, Misconduct and Evidence Preservation 13.3 Submissions, Authorisation Status and Trial Reporting
14 Chapter 14: Current GCP Principles and Delegation
14.1 The Eleven Current GCP Principles 14.2 Proportionality and Investigator Oversight 14.3 Delegation, Qualifications and Task Authority
15 Chapter 15: Oversight, Protocol Control and Amendments
15.1 Clinical Oversight and Immediate-Hazard Changes 15.2 Deviation Classification and Resolution
16 Chapter 16: Implementation and Trial Responsibilities
16.1 Amendment Implementation and Communication 16.2 Sponsor, Investigator and Service-Provider Roles
17 Chapter 17: Quality Planning, Root Causes and CAPA
17.1 Quality Planning and Risk Management 17.2 Root Cause Analysis and CAPA Design 17.3 CAPA Implementation and Effectiveness Verification
18 Chapter 18: Risk Assessment and Monitoring Methods
18.1 Risk Assessment and Centralised Surveillance 18.2 Monitoring Methods and Source Review
19 Chapter 19: Quality Metrics, Plans and Communication
19.1 KRIs, Acceptable Ranges and Trial-Level Quality 19.2 Monitoring Plans, Co-Monitoring and Communication
20 Chapter 20: Site Qualification and Readiness
20.1 Site Qualification and Investigator Capacity 20.2 Recruitment Feasibility and Evidence-Based Site Selection 20.3 Site Readiness and Activity-Specific Release
21 Chapter 21: Initiation, Equipment and Supplies
21.1 Initiation Training and Readiness Walkthroughs 21.2 Equipment, Maintenance and Study Supplies
22 Chapter 22: Samples, Diagnostics and Financial Feasibility
22.1 Specimens, Diagnostic Results and Rater Quality 22.2 Contracts, Budgets and Operational Feasibility
23 Chapter 23: Interim Monitoring and Reporting
23.1 Interim Visit Preparation and Consent Review 23.2 Monitoring Eligibility, Safety and Products 23.3 Investigator Debrief and Monitoring Reports
24 Chapter 24: Essential Records, Audits and Findings
24.1 Essential Records and Site/Sponsor Reconciliation 24.2 Version History, Resolution Evidence and Noncompliance 24.3 Audits, Inspections and Closure Planning
25 Chapter 25: Close-Out, Retention and Destruction
25.1 Close-Out, Archiving and Continuing Obligations 25.2 Retention, Destruction and Long-Term Access
26 Chapter 26: Source Records and Good Documentation
26.1 Source Records and Foundational ALCOA Principles 26.2 Good Documentation, Completeness and Corrections 26.3 Source Access, Certified Copies and Context
27 Chapter 27: Electronic Systems, Metadata and Queries
27.1 EDC Design and Fit-for-Purpose Systems 27.2 Audit Trails, Electronic Outcomes and Device Choice 27.3 Queries, Coding and Supported Clinical Meaning
28 Chapter 28: Dataset Finalisation and Critical Data
28.1 Safety Reconciliation and Dataset Finalisation 28.2 Critical Data, Acquisition Tools and Interim Findings
23.1 Interim Visit Preparation and Consent Review
Key Takeaways Explain This Topic AI
Prepare by reviewing prior actions, emerging data, safety information and needed access.
Consent must precede applicable research activities under the authorised process.
Consent-review coverage follows a justified plan; underlying consent duties apply to every participant.
Last updated: October 2026
Interim Visit Preparation and Consent Review
Note
Under the International Council for Harmonisation (ICH) E6 Good Clinical Practice (GCP) guideline the relevant GCP provisions, the sponsor must ensure that clinical trials are adequately and appropriately monitored. The Interim Monitoring Visit (IMV)—frequently termed the Routine Monitoring Visit (RMV) or Periodic Monitoring Visit (PMV)—represents the primary operational mechanism by which the Clinical Research Associate (CRA) provides on-site oversight. The monitor verifies that the rights and well-being of human participants are protected, that reported clinical trial data are accurate, complete, and verifiable from source records, and that the conduct of the trial adheres strictly to the currently approved protocol, GCP standards, and applicable regulatory requirements.
While Site Selection Visits (SSVs) evaluate institutional capability and Site Initiation Visits (SIVs) launch protocol operations, Interim Monitoring Visits represent the core ongoing operational workload of the CRA during the active clinical conduct phase. Monitoring is neither an informal check-in nor an adversarial confrontation; rather, it is a disciplined, systematic quality control and quality assurance function.
Effective monitoring detects emerging procedural non-compliance, prevents data corruption, reinforces Good Clinical Practice, and protects participant safety before minor deviations compound into systemic study failure.
The Three-Phase IMV Lifecycle
A successful monitoring visit requires systematic execution across three distinct chronological phases:
Phase 1: Pre-Visit Preparation
Effective monitoring begins well before the CRA arrives at the investigative site. Arriving on-site without rigorous preparation wastes limited on-site hours and creates operational blind spots. Pre-visit preparation comprises five mandatory steps:
Previous Visit Reconciliation: The CRA reviews the previous IMV monitoring report, the follow-up letter transmitted to the PI, and the site action item tracker. Every outstanding finding—such as an uncertified medical record, a missing laboratory normal range, or an unresolved pharmacy temperature excursion—is flagged for priority on-site re-examination.
EDC and Query Status Audit: The CRA inspects the electronic data capture (EDC) platform to identify pending site-level queries, query aging metrics (queries unresolved > 14 >14 > 14 or > 30 >30 > 30 days), unentered subject visits, and forms with outstanding investigator electronic signatures.
Protocol Deviation and Safety Screening: The CRA reviews the trial's centralized deviation log and safety database to identify site-specific patterns, such as missed pharmacokinetic draws, out-of-window visits, or discrepancies between site AE logs and safety pharmacovigilance reports.
Enrollment and Interactive Response Technology (IRT): The monitor reviews the IRT / Interactive Web Response System (IWRS) to determine newly screened, randomized, completed, or discontinued participants, ensuring that subject identification numbers match site tracking logs.
The Formal Confirmation Letter: At least 2 to 4 weeks prior to the visit (or per trial-specific monitoring plan timelines), the CRA transmits a written Confirmation Letter to the Principal Investigator and Lead Clinical Research Coordinator (CRC). This letter outlines:
Exact dates and arrival/departure times.
Purpose and primary objectives of the visit.
List of specific subject identification numbers whose medical charts must be pulled or made accessible in the Electronic Medical Record (EMR) system.
Specific facility access requirements (e.g., investigational pharmacy, biological specimen freezers, satellite clinics).
Mandatory appointment time for the Principal Investigator debrief / exit interview.
Phase 2: On-Site Visit Execution
Upon arrival, the monitor establishes a secure, professional workspace. The CRA meets briefly with the Lead CRC to review the day's agenda, confirm investigator availability, verify that requested medical records are unlocked in the EMR, and address immediate site operational questions. The monitor then systematically executes the monitoring workflow outlined below.
Phase 3: Post-Visit Follow-Up
Immediately following the visit, the CRA enters post-visit execution mode. The monitor drafts the formal monitoring report and follow-up letter, documents all identified deviations in the clinical trial management system (CTMS), and initiates tracking of corrective actions.
Step-by-Step On-Site Monitoring Activities
During an on-site visit, the CRA must execute a multi-layered audit across seven foundational clinical and operational domains:
Informed Consent Verification (Risk-Based Verification)
Informed consent is the ethical and legal cornerstone of human subject research. Under ICH E6(R3), obtaining freely given, documented informed consent prior to initiating any protocol-specific procedure is an absolute requirement.
Verification coverage: Consent is critical to participant protection. Follow the justified monitoring plan; ICH does not prescribe a universal 100% SDV percentage. Every participant must still complete the applicable consent process before research activities.
Critical Verification Checklist:
Version Currency: The monitor verifies that the ICF version signed by the subject was the version officially approved by the Institutional Review Board (IRB) / Independent Ethics Committee (IEC) at the exact date and time the consent was executed.
Signature and Date Authenticity: The monitor confirms that the participant (or their legally acceptable representative [LAR], if applicable) signed and dated the consent form themselves, using the approved paper or electronic process. Pre-dating, back-dating, or coordinator-entered dates are critical GCP non-compliances.
Timing Verification: The CRA cross-references the exact timestamp of the signed consent document against the timestamps of the very first study-specific procedures (e.g., screening blood draws, protocol-mandated electrocardiograms, medication washouts). If any protocol-directed intervention occurred prior to obtaining documented consent, a major ethical and regulatory non-compliance has occurred.
Consent Process Note: The CRA audits the medical source record for a contemporaneous progress note documenting the consenting dialogue: that the trial was explained, risks and alternative therapies were discussed, the participant was given adequate time to consider participation, all questions were answered, and a signed, dated copy was provided to the participant.
Re-Consent Compliance: When protocol amendments introduce new safety information, altered visit schedules, or modified procedures, the monitor confirms that all active participants received timely new information and completed updated consent under the approved plan.
Official sources
Checked October 18, 2026: ICH E6(R3), Principles and Annex 1 .